Erbitux Being TAILOR-Made For Chinese First-Line mCRC Market, But Brand Recognition Is Merck's Real Goal
Merck's plans to penetrate the Chinese market further with its anti-EGFR cancer therapy Erbitux (cetuximab) have received a boost with a Phase III TAILOR trial showing significant benefits when used first-line in metastatic colorectal cancer in this population.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.